Pharmacologic advances in the treatment and prevention of respiratory syncytial virus

LD Saravolatz, KM Empey… - Clinical Infectious …, 2010 - academic.oup.com
Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus
(RSV). Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children …

[PDF][PDF] Pharmacologic Advances in the Treatment and Prevention of Respiratory Syncytial Virus

Clinical Infectious Diseases, 2010 - academia.edu
Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus
(RSV). Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children …

Pharmacologic Advances in the Treatment and Prevention of Respiratory Syncytial Virus.

KM Empey, RS Peebles Jr… - Clinical Infectious …, 2010 - search.ebscohost.com
Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus
(RSV). Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children …

Pharmacologic advances in the treatment and prevention of respiratory syncytial virus

KM Empey, RS Peebles Jr… - … infectious diseases: an …, 2010 - pubmed.ncbi.nlm.nih.gov
Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus
(RSV). Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children …

Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.

KM Empey, RSJ Peebles, JK Kolls - 2010 - cabidigitallibrary.org
Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus
(RSV). Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children …

[HTML][HTML] Pharmacologic Advances in the Treatment and Prevention of Respiratory Syncytial Virus

KM Empey, RS Peebles Jr, JK Kolls - Clinical infectious diseases …, 2010 - ncbi.nlm.nih.gov
There are currently only two drugs approved for respiratory syncytial virus (RSV).
Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children and …

Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.

KM Empey, RS Peebles Jr, JK Kolls - Clinical Infectious Diseases …, 2010 - europepmc.org
There are currently only two drugs approved for respiratory syncytial virus (RSV).
Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children and …

Phannacologic Advances in the Treatment and Prevention of Respiratory Syncytial Virus

KM Empey, RS Peebles Jr, JK Kolls - Clinical Infectious Diseases, 2010 - JSTOR
Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus
(RSV). Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children …

Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.

KM Empey, RS Peebles Jr, JK Kolls - Clinical Infectious Diseases …, 2010 - europepmc.org
There are currently only two drugs approved for respiratory syncytial virus (RSV).
Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children and …

[引用][C] Pharmacologic Advances in the Treatment and Prevention of Respiratory Syncytial Virus

LD Saravolatz, KM Empey… - Clinical infectious …, 2010 - Oxford University Press